CJC-1295 DAC

CJC-1295 DAC is a long-acting growth hormone-releasing hormone (GHRH) analog designed to stimulate the anterior pituitary gland to increase growth hormone secretion. In the body, GHRH is naturally released in pulses that alternate with somatostatin, a hormone responsible for inhibiting growth hormone release.

CJC-1295 + DAC is widely recognized in peptide research for its extended duration of action. The DAC (Drug Affinity Complex) component prolongs the peptide’s half-life by enabling it to bind to serum albumin, which helps protect it from rapid degradation. This stabilization is achieved through the attachment of a lysine linker to the DAC using the reactive compound maleimidopropionic acid (MPA).

Research use:

• Growth & Development: Potential to support sustained GH release and its effects on tissue growth, bone development, and muscle maintenance.
• Metabolism: How prolonged GH activity may influence fat breakdown, protein synthesis, and glucose regulation.
• Tissue Repair & Regeneration: For possible roles in supporting muscle, cartilage, and other tissue repair processes in experimental models.
• Immune Function: Examine whether extended GH release may affect immune cell activity and cytokine signalling.
• Cellular Aging & Longevity: How GH modulation may relate to cellular aging processes and longevity markers.
• Cognition: Effects on brain function, including neuroprotection and cognitive processes.
• Cardiovascular Research: How sustained GH exposure may influence heart function, vascular health, and lipid metabolism.